Humulin 30/70 (Miscela)

Humulin 30/70 is a mixed insulin formulation containing recombinant human insulin (rDNA) at a concentration of 100 U/mL, composed of 30 % soluble insulin and 70 % protamine‑bound insulin. It is supplied as an injectable solution for subcutaneous administration and is marketed in the European Union as an antidiabetic medication. It is indicated for the management of blood glucose in adults with type 1 or type 2 diabetes and is classified under ATC code A10AD02.

Humulin 30/70 is used as part of a comprehensive diabetes management plan to control hyperglycemia in patients who require both rapid‑acting and intermediate‑acting insulin coverage.

- Initiation of basal‑bolus therapy in adults with type 1 diabetes mellitus. - Supplemental insulin for type 2 diabetes when oral agents no longer achieve target glucose. - Management of post‑prandial glucose excursions in patients with variable meal patterns. - Use during pregnancy only when benefits outweigh potential risks, under specialist supervision. - Adjustment of dose in response to changes in diet, physical activity, or illness.

Adverse reactions to Humulin 30/70 are generally related to its insulin activity and to injection‑site tolerance.

Common: - Hypoglycemia, especially if meals are delayed or doses are mismatched. - Injection‑site pain, redness, or swelling. - Lipodystrophy presenting as localized lipoatrophy or lipohypertrophy. - Mild weight gain associated with improved glycemic control. - Transient visual disturbances such as blurred vision during rapid glucose changes. - Nausea or mild gastrointestinal discomfort.

Serious: - Severe hypoglycemia with neuroglycopenic symptoms such as confusion or seizures. - Allergic reactions ranging from urticaria to anaphylaxis. - Persistent edema or heart failure exacerbation in susceptible patients. - Unexplained hypokalemia secondary to rapid glucose shifts. - Severe allergic edema (angioedema) involving airway compromise.

When prescribing Humulin 30/70, clinicians should evaluate patient-specific factors and monitor for conditions that may alter insulin requirements or increase risk of adverse events.

- Assess renal and hepatic function, as impairment can prolong insulin action. - Review history of hypoglycemia unawareness before initiating therapy. - Adjust doses during periods of illness, surgery, or significant changes in physical activity. - Counsel patients on proper injection technique to minimize lipodystrophy. - Monitor weight, blood pressure, and signs of fluid retention regularly. - Use caution in pregnant or breastfeeding women; benefits must outweigh potential risks.

Humulin 30/70 may interact with other medicines that affect glucose metabolism, insulin sensitivity, or the pharmacokinetics of insulin.

Avoid: - Concomitant use of other rapid‑acting insulins or insulin analogues without dose adjustment. - Beta‑blockers that mask hypoglycemia symptoms. - High‑dose corticosteroids that markedly increase insulin resistance. - Concurrent use of growth hormone therapy, which can antagonize insulin action.

Use with caution: - Thiazide diuretics, which may raise blood glucose levels. - ACE inhibitors or ARBs, which can potentiate insulin’s antihypertensive effect. - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk. - Alcohol consumption, which can cause delayed hypoglycemia. - Pregnancy hormones may alter insulin requirements; close monitoring is required.